MA38156A1 - Utilisation du pidotimod pour traiter la dermatite atopique - Google Patents
Utilisation du pidotimod pour traiter la dermatite atopiqueInfo
- Publication number
- MA38156A1 MA38156A1 MA38156A MA38156A MA38156A1 MA 38156 A1 MA38156 A1 MA 38156A1 MA 38156 A MA38156 A MA 38156A MA 38156 A MA38156 A MA 38156A MA 38156 A1 MA38156 A1 MA 38156A1
- Authority
- MA
- Morocco
- Prior art keywords
- pidotimod
- atopic dermatitis
- treat atopic
- acceptable salt
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention porte sur l'utilisation du pidotimod, ou d'un sel physiologiquement acceptable, pour traiter la dermatite atopique. Dans le cadre du traitement de la présente invention, le pidotimod ou son sel physiologiquement acceptable, est administré de préférence par voie topique.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/076086 WO2014094839A1 (fr) | 2012-12-19 | 2012-12-19 | Utilisation du pidotimod pour traiter la dermatite atopique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38156A1 true MA38156A1 (fr) | 2016-08-31 |
| MA38156B1 MA38156B1 (fr) | 2017-03-31 |
Family
ID=47520053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38156A MA38156B1 (fr) | 2012-12-19 | 2012-12-19 | Utilisation du pidotimod pour traiter la dermatite atopique |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20150352081A1 (fr) |
| EP (1) | EP2934520B1 (fr) |
| JP (1) | JP6058156B2 (fr) |
| KR (1) | KR20150095772A (fr) |
| CN (1) | CN104797254B (fr) |
| AU (1) | AU2012396941A1 (fr) |
| BR (1) | BR112015011394A2 (fr) |
| CA (1) | CA2889388A1 (fr) |
| CY (1) | CY1118633T1 (fr) |
| DK (1) | DK2934520T3 (fr) |
| EA (1) | EA201591184A1 (fr) |
| EC (1) | ECSP15025570A (fr) |
| ES (1) | ES2615748T3 (fr) |
| HK (1) | HK1210938A1 (fr) |
| HR (1) | HRP20161667T1 (fr) |
| HU (1) | HUE030408T2 (fr) |
| IL (1) | IL239292A0 (fr) |
| LT (1) | LT2934520T (fr) |
| MA (1) | MA38156B1 (fr) |
| ME (1) | ME02559B (fr) |
| MX (1) | MX2015008129A (fr) |
| PH (1) | PH12015501211A1 (fr) |
| PL (1) | PL2934520T3 (fr) |
| PT (1) | PT2934520T (fr) |
| RS (1) | RS55424B1 (fr) |
| SG (1) | SG11201503281QA (fr) |
| SI (1) | SI2934520T1 (fr) |
| SM (1) | SMT201700071B (fr) |
| TN (1) | TN2015000159A1 (fr) |
| UY (1) | UY35197A (fr) |
| WO (1) | WO2014094839A1 (fr) |
| ZA (1) | ZA201502983B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015036009A1 (fr) * | 2013-09-10 | 2015-03-19 | Polichem S.A. | Pidotimod à utiliser dans le traitement de maladies associées à une inflammation |
| EP3754806A1 (fr) | 2019-06-19 | 2020-12-23 | UTC Fire & Security EMEA BVBA | Dispositif d'alimentation électrique |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231723B (it) * | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
| JP2005511627A (ja) * | 2001-11-20 | 2005-04-28 | シアトル ジェネティクス，インコーポレーテッド | 抗ｃｄ３０抗体を使用する免疫学的疾患の治療 |
| EP1688161A1 (fr) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Utilisation du pirlindole dans le traitement des maladies caracterisées par la prolifération des lymphocytes t et/ou par l'hyperproliferation de kerationcytes, notamment la dermatite atopique et le psoriasis |
| TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
-
2012
- 2012-12-19 SG SG11201503281QA patent/SG11201503281QA/en unknown
- 2012-12-19 SI SI201230863A patent/SI2934520T1/sl unknown
- 2012-12-19 MX MX2015008129A patent/MX2015008129A/es unknown
- 2012-12-19 MA MA38156A patent/MA38156B1/fr unknown
- 2012-12-19 ME MEP-2016-275A patent/ME02559B/fr unknown
- 2012-12-19 WO PCT/EP2012/076086 patent/WO2014094839A1/fr active Application Filing
- 2012-12-19 HU HUE12812220A patent/HUE030408T2/en unknown
- 2012-12-19 PL PL12812220T patent/PL2934520T3/pl unknown
- 2012-12-19 JP JP2015548220A patent/JP6058156B2/ja not_active Expired - Fee Related
- 2012-12-19 BR BR112015011394A patent/BR112015011394A2/pt not_active IP Right Cessation
- 2012-12-19 CA CA2889388A patent/CA2889388A1/fr not_active Abandoned
- 2012-12-19 KR KR1020157018214A patent/KR20150095772A/ko not_active Application Discontinuation
- 2012-12-19 PT PT128122207T patent/PT2934520T/pt unknown
- 2012-12-19 DK DK12812220.7T patent/DK2934520T3/en active
- 2012-12-19 CN CN201280077173.2A patent/CN104797254B/zh active Active
- 2012-12-19 EA EA201591184A patent/EA201591184A1/ru unknown
- 2012-12-19 LT LTEP12812220.7T patent/LT2934520T/lt unknown
- 2012-12-19 RS RS20161045A patent/RS55424B1/sr unknown
- 2012-12-19 AU AU2012396941A patent/AU2012396941A1/en not_active Abandoned
- 2012-12-19 EP EP12812220.7A patent/EP2934520B1/fr active Active
- 2012-12-19 US US14/652,472 patent/US20150352081A1/en not_active Abandoned
- 2012-12-19 ES ES12812220.7T patent/ES2615748T3/es active Active
-
2013
- 2013-12-17 UY UY0001035197A patent/UY35197A/es not_active Application Discontinuation
-
2015
- 2015-04-24 TN TNP2015000159A patent/TN2015000159A1/fr unknown
- 2015-04-30 ZA ZA2015/02983A patent/ZA201502983B/en unknown
- 2015-05-29 PH PH12015501211A patent/PH12015501211A1/en unknown
- 2015-06-08 IL IL239292A patent/IL239292A0/en unknown
- 2015-06-16 EC ECIEPI201525570A patent/ECSP15025570A/es unknown
- 2015-11-26 HK HK15111636.0A patent/HK1210938A1/xx not_active IP Right Cessation
-
2016
- 2016-12-07 HR HRP20161667TT patent/HRP20161667T1/hr unknown
-
2017
- 2017-01-30 SM SM201700071T patent/SMT201700071B/it unknown
- 2017-02-14 CY CY20171100199T patent/CY1118633T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201301354A1 (ru) | Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками | |
| EA201990951A1 (ru) | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
| MY189333A (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| MX2015005538A (es) | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. | |
| EA201290836A1 (ru) | Связанные бис-арильные арилтриазолоны и их применение | |
| MA34045B1 (fr) | Ligands sigma destinés à être utilisés pour la prévention et/ou le traitement de la douleur postopératoire | |
| MY165160A (en) | TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS | |
| MA39710A (fr) | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin | |
| MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| EA201492102A1 (ru) | Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны | |
| WO2016094899A3 (fr) | Traitement d'une l'inflammation médiée par hmgb1 | |
| MX2017000306A (es) | Metodos para tratar hipotension. | |
| AU2017261919A1 (en) | Fat and medical uses thereof | |
| CA3010788A1 (fr) | Procedes d'administration de vasopresseurs | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| MA38156A1 (fr) | Utilisation du pidotimod pour traiter la dermatite atopique | |
| MA38155B1 (fr) | Utilisation du pidotimod pour traiter le psoriasis | |
| MA41142A (fr) | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement | |
| MA44660B1 (fr) | (+) -azasetron pour son utilisation dans le traitement des troubles de l'oreille | |
| TR201903234T4 (tr) | Parkinson hastalığının tedavisinde kullanılmaya yönelik dopamin içeren farmasötik çözelti. | |
| EA201790537A1 (ru) | Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира | |
| MX2020012464A (es) | Formulaciones de dantroleno y metodos de uso de dichas formulaciones. | |
| FR3008317B1 (fr) | Utilisation de microorganismes pour diminuer le taux de trimethylamine dans une cavite du corps humain, notamment pour le traitement de la trimethylaminurie ou d'une vaginose bacterienne et la prevention des maladies cardiovasculaires | |
| MA37930A1 (fr) | Procédés pour le traitement du cancer utilisant le lipoplatine | |
| MX2016013889A (es) | Medicamento. |